Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy options in imatinib failures.

Pablo Ramirez1, John F DiPersio

  • 1Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8007, St. Louis, Missouri 63110, USA. jdipersi@im.wustl.edu

The Oncologist
|May 2, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

Nature medicine·2026
Same author

Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell Disease.

The New England journal of medicine·2026
Same author

NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Nature communications·2026
Same author

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Blood·2026
Same author

Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning.

Blood immunology & cellular therapy·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
Same journal

Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.

The oncologist·2026
See all related articles

Newer tyrosine kinase inhibitors like dasatinib and nilotinib offer improved outcomes for chronic myelogenous leukemia (CML) patients resistant to imatinib. These agents target Bcr-Abl and related kinases, addressing resistance mechanisms and improving survival rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic myelogenous leukemia (CML) is characterized by the Bcr-Abl tyrosine kinase, driving uncontrolled cell proliferation.
  • Imatinib revolutionized CML treatment, but resistance and intolerance limit its efficacy in some patients.
  • Resistance mechanisms include Bcr-Abl mutations and activation of alternative signaling pathways.

Purpose of the Study:

  • To review current treatment strategies for CML.
  • To discuss novel tyrosine kinase inhibitors (TKIs) for imatinib-resistant or intolerant CML.
  • To highlight the efficacy and safety of dasatinib and nilotinib.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of resistance mechanisms to imatinib.

Related Experiment Videos

  • Evaluation of the efficacy and safety profiles of second-generation TKIs.

    • Main Results:

    • Dasatinib and nilotinib demonstrate significant efficacy in patients resistant or intolerant to imatinib.
    • These agents target Bcr-Abl and related kinases, overcoming common resistance mutations.
    • Dasatinib is effective against most Bcr-Abl mutations, excluding T315I.

    Conclusions:

    • Second-generation TKIs represent crucial advancements in CML management.
    • Dasatinib and nilotinib offer effective therapeutic options for a broader range of CML patients.
    • Further research into novel strategies is needed for T315I-mutated CML and other resistance mechanisms.